EA200900212A1 - Элементы нуклеиновых кислот, обладающие регуляторной функцией - Google Patents
Элементы нуклеиновых кислот, обладающие регуляторной функциейInfo
- Publication number
- EA200900212A1 EA200900212A1 EA200900212A EA200900212A EA200900212A1 EA 200900212 A1 EA200900212 A1 EA 200900212A1 EA 200900212 A EA200900212 A EA 200900212A EA 200900212 A EA200900212 A EA 200900212A EA 200900212 A1 EA200900212 A1 EA 200900212A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- elements
- gene
- well
- expression
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В заявке описаны последовательности ДНК, прежде всего усиливающие транскрипцию или экспрессию элементы (ТЕ-элементы), а также их применение в экспрессионном векторе в сочетании с энхансером, промотором, геном продукта и селектируемым маркером. В заявке описаны также последовательность SEQ ID NO: 1, а также ТЕ-элементы ТЕ-01, -02, -03, -04, -06, -07, -08, -10, -11 или -12. Наиболее предпочтительными являются ТЕ-06, ТЕ-07 или ТЕ-08, что обусловлено их небольшим размером. Последовательность NO: 1 выведена из области последовательности, расположенной против хода транскрипции относительно кодирующей области гена Ub/S27a из СНО-клеток. ТЕ-элементы вызывают усиление экспрессии гена продукта при стабильной интеграции в эукариотический геном, предпочтительно геном CHO-DG44-клетки. Это позволяет преодолевать хромосомальные позиционные воздействия, защищать от них или устранять их. В результате этого достигается повышение доли высокопродуктивных клеток в трансфектированной смеси, а также абсолютного уровня экспрессии вплоть до 15 раз.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06117862 | 2006-07-26 | ||
PCT/EP2007/055954 WO2008012142A1 (de) | 2006-07-26 | 2007-06-15 | Regulatorische nukleinsäureelemente |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200900212A1 true EA200900212A1 (ru) | 2009-10-30 |
EA016880B1 EA016880B1 (ru) | 2012-08-30 |
Family
ID=37441548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900212A EA016880B1 (ru) | 2006-07-26 | 2007-06-15 | Элементы нуклеиновых кислот, обладающие регуляторной функцией |
Country Status (23)
Country | Link |
---|---|
US (3) | US20080124760A1 (ru) |
EP (1) | EP2049671B1 (ru) |
JP (1) | JP5270544B2 (ru) |
KR (1) | KR101485853B1 (ru) |
CN (1) | CN101517085B (ru) |
AR (1) | AR061472A1 (ru) |
AU (1) | AU2007278368B2 (ru) |
BR (1) | BRPI0714594A2 (ru) |
CA (1) | CA2658595C (ru) |
CY (1) | CY1113711T1 (ru) |
DK (1) | DK2049671T3 (ru) |
EA (1) | EA016880B1 (ru) |
ES (1) | ES2401654T3 (ru) |
HK (1) | HK1134107A1 (ru) |
IL (1) | IL196676A0 (ru) |
MX (1) | MX2009000781A (ru) |
NO (1) | NO20090057L (ru) |
NZ (1) | NZ575115A (ru) |
PL (1) | PL2049671T3 (ru) |
PT (1) | PT2049671E (ru) |
SI (1) | SI2049671T1 (ru) |
TW (1) | TW200815591A (ru) |
WO (1) | WO2008012142A1 (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
DK2697375T3 (en) | 2011-04-13 | 2018-01-15 | Nat Res Council Canada | EXPRESSION SYSTEM WITH A SAR (SCAFFOLD ATTACHMENT REGION) ELEMENT OF INTERFERON 2 |
SG11201401857WA (en) | 2011-10-28 | 2014-09-26 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
UA115439C2 (uk) | 2012-01-27 | 2017-11-10 | Протена Біосаєнсиз Лімітед | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
US9850302B2 (en) | 2013-07-12 | 2017-12-26 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
US11191832B2 (en) | 2013-11-19 | 2021-12-07 | Prothena Biosciences Limited | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
US10059761B2 (en) | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
JP6871174B2 (ja) * | 2015-02-02 | 2021-05-12 | メイラグティーエックス ユーケー アイアイ リミティド | 選択的スプライシングのアプタマー媒介性調節による遺伝子発現の調節 |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
CU24636B1 (es) | 2017-05-02 | 2022-12-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 |
WO2019064053A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES |
WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
CA3117816A1 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
JP7412860B2 (ja) | 2020-10-16 | 2024-01-15 | 株式会社奥村組 | 泥水式シールド掘進機および泥水式シールド掘進機における圧縮空気の圧力調整方法 |
CA3217224A1 (en) * | 2021-04-21 | 2022-10-27 | Janssen Biotech, Inc. | Materials and methods for improved phosphotransferases |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
DK0393438T3 (da) | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
AU650085B2 (en) | 1990-11-13 | 1994-06-09 | Immunex Corporation | Bifunctional selectable fusion genes |
US5786166A (en) | 1991-10-25 | 1998-07-28 | University Of Tennessee Research Corporation | Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
DE19539493A1 (de) * | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
DK0873405T3 (da) * | 1996-01-11 | 2005-01-17 | Immunex Corp | Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer |
WO2000034326A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034325A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
JP4618891B2 (ja) | 1998-12-11 | 2011-01-26 | クロンテック・ラボラトリーズ・インコーポレーテッド | Anthozoa綱の非生物発光性種由来の蛍光タンパク質、そのようなタンパク質をコードする遺伝子、およびそれらの使用 |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
DK1196566T3 (da) | 1999-07-12 | 2006-06-06 | Genentech Inc | Ekspressionsvektorer og -metoder |
AU783767B2 (en) | 1999-10-14 | 2005-12-01 | Takara Bio Usa, Inc. | Anthozoa derived chromophores/fluorophores and methods for using the same |
CA2443275C (en) | 2001-04-05 | 2013-02-05 | Ml Laboratories Plc | Improved gene expression |
ATE474053T1 (de) | 2001-07-04 | 2010-07-15 | Chromagenics Bv | Dns-sequenzen mit anti-repressor-aktivität |
KR101149777B1 (ko) | 2002-11-29 | 2012-06-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법 |
US7344886B2 (en) | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
DE10256083A1 (de) | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
-
2007
- 2007-06-13 US US11/762,240 patent/US20080124760A1/en not_active Abandoned
- 2007-06-14 TW TW096121483A patent/TW200815591A/zh unknown
- 2007-06-15 MX MX2009000781A patent/MX2009000781A/es active IP Right Grant
- 2007-06-15 EA EA200900212A patent/EA016880B1/ru not_active IP Right Cessation
- 2007-06-15 DK DK07730192.7T patent/DK2049671T3/da active
- 2007-06-15 CA CA2658595A patent/CA2658595C/en active Active
- 2007-06-15 PT PT77301927T patent/PT2049671E/pt unknown
- 2007-06-15 CN CN2007800359296A patent/CN101517085B/zh active Active
- 2007-06-15 JP JP2009521178A patent/JP5270544B2/ja active Active
- 2007-06-15 SI SI200731174T patent/SI2049671T1/sl unknown
- 2007-06-15 NZ NZ575115A patent/NZ575115A/en not_active IP Right Cessation
- 2007-06-15 ES ES07730192T patent/ES2401654T3/es active Active
- 2007-06-15 EP EP07730192A patent/EP2049671B1/de active Active
- 2007-06-15 KR KR1020097004079A patent/KR101485853B1/ko active IP Right Grant
- 2007-06-15 AU AU2007278368A patent/AU2007278368B2/en active Active
- 2007-06-15 AR ARP070102632A patent/AR061472A1/es active Pending
- 2007-06-15 PL PL07730192T patent/PL2049671T3/pl unknown
- 2007-06-15 WO PCT/EP2007/055954 patent/WO2008012142A1/de active Application Filing
- 2007-06-15 BR BRPI0714594-2A patent/BRPI0714594A2/pt not_active IP Right Cessation
-
2009
- 2009-01-06 NO NO20090057A patent/NO20090057L/no not_active Application Discontinuation
- 2009-01-22 IL IL196676A patent/IL196676A0/en unknown
-
2010
- 2010-01-28 HK HK10100907.0A patent/HK1134107A1/xx not_active IP Right Cessation
- 2010-07-23 US US12/842,468 patent/US9045776B2/en active Active
-
2013
- 2013-02-21 CY CY20131100160T patent/CY1113711T1/el unknown
-
2015
- 2015-04-29 US US14/699,182 patent/US9708626B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2049671B1 (de) | 2012-12-19 |
US20150337333A1 (en) | 2015-11-26 |
JP2009544293A (ja) | 2009-12-17 |
MX2009000781A (es) | 2009-01-29 |
ES2401654T3 (es) | 2013-04-23 |
SI2049671T1 (sl) | 2013-04-30 |
JP5270544B2 (ja) | 2013-08-21 |
CA2658595C (en) | 2016-05-31 |
US20080124760A1 (en) | 2008-05-29 |
PT2049671E (pt) | 2013-01-24 |
EP2049671A1 (de) | 2009-04-22 |
BRPI0714594A2 (pt) | 2013-02-19 |
AU2007278368B2 (en) | 2013-12-19 |
DK2049671T3 (da) | 2013-04-08 |
NO20090057L (no) | 2009-02-16 |
PL2049671T3 (pl) | 2013-05-31 |
HK1134107A1 (en) | 2010-04-16 |
EA016880B1 (ru) | 2012-08-30 |
KR20090046887A (ko) | 2009-05-11 |
IL196676A0 (en) | 2011-08-01 |
WO2008012142A1 (de) | 2008-01-31 |
NZ575115A (en) | 2011-10-28 |
AU2007278368A1 (en) | 2008-01-31 |
KR101485853B1 (ko) | 2015-01-23 |
US9045776B2 (en) | 2015-06-02 |
AR061472A1 (es) | 2008-08-27 |
US20100311121A1 (en) | 2010-12-09 |
CA2658595A1 (en) | 2008-01-31 |
CY1113711T1 (el) | 2016-06-22 |
CN101517085A (zh) | 2009-08-26 |
CN101517085B (zh) | 2013-08-07 |
TW200815591A (en) | 2008-04-01 |
US9708626B2 (en) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200900212A1 (ru) | Элементы нуклеиновых кислот, обладающие регуляторной функцией | |
DE60228212D1 (de) | Neue expressionsvektoren | |
DE602004031041D1 (de) | In pflanzenplastiden funktionsfähiger promotor | |
ATE386127T1 (de) | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie | |
EA200801462A1 (ru) | Связывающий днк-сайт активатора транскрипции, пригодный для экспрессии генов | |
JP2013505013A5 (ru) | ||
MX338183B (es) | Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas quie expresan los mismos y metodos para usarlos. | |
EA201100225A1 (ru) | Новые регуляторные элементы | |
WO2006013103A3 (de) | Induzierbare genexpression | |
ATE510920T1 (de) | Dna-sequenzen zur regulation der transkription | |
HK1216387A1 (zh) | 用於生產蛋白的轉基因蘆薈植物及其相關的方法 | |
WO2008133137A1 (ja) | 遺伝子治療のためのベクター | |
NZ591439A (en) | pCAGGS VECTOR COMPRISING AN 829 BASE PAIR DELETION IN THE CHICKEN-BETA ACTIN INTRON WHICH RESULTS IN ENHANCED EXPRESSION OF A GENE OF INTEREST | |
RU2012130149A (ru) | Векторная система на основе aslv | |
HUP0101355A2 (hu) | Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák | |
NZ608144A (en) | Sugarcane bacilliform viral (scbv) enhancer and its use in plant functional genomics | |
EP1149917A3 (en) | Hepatitis B virus vectors for gene therapy | |
MXPA05011774A (es) | Gen de factor de transcripcion inducido por condiciones de deficit de agua y acido abscisico a partir de helianthus annuus, promotor y plantas transgenicas. | |
CA2429451A1 (en) | Isolated luciferases and their use | |
Sadikoglou et al. | Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression | |
BR0309870A (pt) | Composições e métodos para a modificação de expressão de genes usando o promotor de superubiquitina de pinus radiata | |
JP4719670B2 (ja) | N−myc発現腫瘍におけるヒトN−myc遺伝子のアンチセンスおよびアンチジーンペプチド核酸(PNA)による選択的阻害法 | |
EA200500873A1 (ru) | Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита | |
Engstrom et al. | 1056. Suppression and Enhancement of Gene Repair by the Modulation of ATM Function in Mammalian Cells | |
CN100480261C (zh) | 核基质蛋白结合序列及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |